Original articleTreatment of erythrodermic psoriasis with biologics: A systematic review
Section snippets
Search strategy
This review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.8 A primary literature search was conducted with the databases PubMed, Scopus, Embase, and Cochrane Library. We identified eligible articles from database inception to December 31, 2018. The search terms were “biologics” and “erythrodermic psoriasis,” “biologic” and “erythrodermic psoriasis,” “(drug name)” and “erythrodermic psoriasis.” Drug names included secukinumab, ixekizumab,
Systematic search results
We included 43 articles yielding 179 patients with EP treated with biologic medications (Fig 1). Case reports comprised 65.1% of the articles, followed by case series (14.0%) and open-label studies (11.6%). There were 3 retrospective studies and 1 open prospective study. Sixteen articles reported treatment with infliximab,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 10 with ustekinumab,32, 33, 34, 35, 36, 37, 38, 39, 40, 41 4 with etanercept,42, 43, 44, 45 5 with secukinumab,46
Discussion
We aim to update the recommendations for treating EP with biologics published by Levin et al7 in 2012. Since their publication, new biologics have been approved for the treatment of plaque psoriasis. There is a lack of randomized, double-blind, controlled trials and head-to-head comparisons. Therefore, recommending any of the biologics as a first-line treatment for the management of EP is a challenge. Recommendations for each biologic are presented in Table II. Overall, ustekinumab was the most
Conclusion
Biologic therapy in patients with EP seems to be well-tolerated and demonstrated a positive response. Recommendations for biologic agent therapy in EP are based on limited evidence. We recommend infliximab or ustekinumab in acute, severe cases of EP as first-line biologic agents. IL-23 and IL-17 inhibitor agents seem to be a promising category of biologic treatment of EP and can also be considered as first-line therapy based on their level of evidence. Etanercept and adalimumab can be used in
References (58)
Psoriasis
Lancet
(2003)- et al.
Diagnosis and classification of psoriasis
Autoimmun Rev
(2014) - et al.
Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation
J Am Acad Dermatol
(2010) - et al.
Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: a systematic review
Pancreatology
(2017) - et al.
Systematic review of acute pancreatitis associated with interferon-α or pegylated interferon-α: possible or definitive causation?
Pancreatology
(2018) - et al.
Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report
Radiol Case Rep
(2018) - et al.
Infliximab: an alternative in refractory erythrodermic psoriasis
Piel
(2006) - et al.
Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis
J Dermatol Sci
(2015) - et al.
Psoriatic erythroderma treated with etanercept [in Spanish]
Actas Dermosifiliogr
(2007) - et al.
Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
JAAD Case Rep
(2018)
Psoriasis—epidemiology and clinical spectrum
Clin Exp Dermatol
A review of the clinical variants and the management of psoriasis
Adv Skin Wound Care
Erythrodermic psoriasis: pathophysiology and current treatment perspectives
Psoriasis (Auckl)
Biologic therapy in erythrodermic and pustular psoriasis
J Drugs Dermatol
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Open Med
Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: a case study and systematic analysis of the literature
Neurogastroenterol Motil
Metal stents versus plastic stents for the management of pancreatic walled-off necrosis: a systematic review and meta-analysis
Gastrointest Endosc
Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?
Gastroenterol Rep
Systematic reviews: grading recommendations and evidence quality
Arch Dermatol
Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade) [in Spanish]
Rev Med Chil
Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis
An Bras Dermatol
Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab
J Dermatolog Treat
Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis
Br J Dermatol
Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis
Acta Derm Venereol
From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis
Australas J Dermatol
The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases
Arch Dermatol
Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)
Ann Rheum Dis
Life-threatening pustular and erythrodermic psoriasis responding to infliximab
J Drugs Dermatol
Cited by (0)
Funding sources: None.
Conflicts of interest: None disclosed.
IRB approval status: Not necessary for this systematic review due to all the data being taken from public, anonymous literature.
Reprints are not available from the authors.